What Truxima treats
Truxima (rituximab-abbs) is a biosimilar to Rituxan, approved for the treatment of several autoimmune conditions and blood cancers. It is used in the management of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), and moderate to severe rheumatoid arthritis (RA), among other indications. Truxima works by targeting and depleting B cells, which play a key role in autoimmune activity and certain types of cancer.
Benefits of Truxima
Patients using Truxima may experience:
- Tumor reduction and delayed progression in blood cancers
- Reduced joint pain, swelling, and fatigue in RA
- Fewer disease flares and improved physical function
- A cost-effective alternative to branded rituximab
Biosimilar access can improve continuity of care while maintaining high clinical standards.
Possible Side Effects of Truxima
Common side effects may include:
- Infusion-related reactions (fever, chills, rash, shortness of breath)
- Fatigue
- Headache
- Nausea
- Increased risk of infections (especially upper respiratory infections)
Serious but rare risks include:
- Severe infusion reactions
- Hepatitis B reactivation
- Progressive multifocal leukoencephalopathy (PML)
- Serious infections and cardiac events
Pre-treatment screening and monitoring during infusions are essential to ensure safety.
How infusion works at Prime
Truxima is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Truxima, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Truxima Work?
Truxima works by binding to the CD20 protein found on the surface of B lymphocytes (B cells). This triggers the destruction of these cells, which are involved in producing the antibodies responsible for autoimmune attacks or contributing to cancer cell growth. By depleting B cells, Truxima helps reduce inflammation, slow disease progression, and improve clinical outcomes. It is administered via intravenous infusion, with dosing schedules dependent on the specific condition being treated.
Who is Truxima For?
Truxima is FDA-approved for:
- Adults with non-Hodgkin’s lymphoma (NHL)
- Adults with chronic lymphocytic leukemia (CLL)
- Adults with moderate to severe rheumatoid arthritis (in combination with methotrexate) who have had an inadequate response to one or more TNF antagonist therapies
- Additional off-label or emerging uses in certain autoimmune diseases (at the discretion of specialists)
As a biosimilar, Truxima offers equivalent safety and efficacy to Rituxan, often at a reduced cost.